Literature DB >> 12633155

The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab.

Jeffrey M Katz1, Michiko Kimura Bruno, Jacqueline M S Winterkorn, Nancy Nealon.   

Abstract

OBJECTIVE: To review the pathogenesis and treatment of optic disc swelling in neurosarcoidosis, including a novel therapeutic response to infliximab. DESIGN AND
SETTING: Case reports from an inpatient neurology service. PATIENTS: A 35-year-old woman presented with headache, chronic visual loss, papilledema, and optic atrophy, characteristic of chronic intracranial hypertension. Magnetic resonance imaging showed bifrontal cerebral edema with en plaque frontal pachymeningeal enhancement. Her visual loss progressed despite conventional therapies. The use of the tumor necrosis factor alpha antagonist infliximab maintained functional vision in her right eye. A 57-year-old woman presented with bilateral, subacute, painful visual loss and unilateral papillitis consistent with optic neuritis. Her visual loss responded rapidly to intravenous corticosteroids. The funduscopic examination findings in both patients prompted further clinical investigation, culminating in the diagnosis of neurosarcoidosis.
CONCLUSION: Understanding the multiple etiologic mechanisms that produce optic disc swelling in sarcoidosis can help neurologists tailor treatment for patients with neurosarcoidosis who present with this symptom.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633155     DOI: 10.1001/archneur.60.3.426

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

Review 1.  Neuro-ophthalmic sarcoidosis.

Authors:  Robert P Baughman; Kenneth L Weiss; Karl C Golnik
Journal:  Eye Brain       Date:  2012-03-13

2.  Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit.

Authors:  Panagiotis G Theodossiadis; Vasilios S Liarakos; Petros P Sfikakis; Alexander Charonis; Georgios Agrogiannis; Nikolaos Kavantzas; Ioannis A Vergados
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

Review 3.  SEVERE PANUVEITIS, RETINAL VASCULITIS, AND OPTIC DISK GRANULOMA SECONDARY TO SARCOIDOSIS.

Authors:  Michael Patterson; Chris S Bergstrom; W Lloyd Clark; Hans E Grossniklaus; John F Payne
Journal:  Retin Cases Brief Rep       Date:  2016

4.  Neuro-ophthalmologic Manifestations of Sarcoidosis.

Authors:  Barney J Stern; James Corbett
Journal:  Curr Treat Options Neurol       Date:  2007-01       Impact factor: 3.598

5.  Headache as presenting symptom of neurosarcoidosis.

Authors:  M Curone; V Tullo; C Peccarisi; G Bussone; D D'Amico
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

6.  Neurosarcoidosis.

Authors:  Ashok V Patel; David E Stickler; William R Tyor
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

7.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

8.  Optic nerve head granuloma as a primary manifestation of ocular sarcoidosis - A tertiary uveitis clinic experience.

Authors:  Sudha K Ganesh; Anushree Vijay Kaduskar
Journal:  Oman J Ophthalmol       Date:  2015 Sep-Dec

9.  Unusual Primary Ocular Manifestation of Sarcoidosis.

Authors:  Svenja Deuchler; Clemens Wagner; Markus Schill; Benjamin Schöne; Daniel Scherer; Pankaj Singh; Thomas Kohnen; Frank H J Koch
Journal:  Case Rep Ophthalmol       Date:  2019-07-03

10.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.